fb tracking

Comments Submitted to CMS Regarding the Proposed National Coverage Determination for Aducanumab for Treatment of Alzheimer’s Disease

View as PDF

Public Citizen strongly supports the Centers for Medicare and Medicaid Services’ (CMS’) proposed national coverage determination for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (CAG-00460N), under which the Medicare program would cover the drug aducanumab only for beneficiaries who enroll in CMS-approved randomized, controlled clinical trials meeting certain criteria or in trials supported by the National Institutes of Health.

See Public Citizen’s other work on aducanumab.